Benign Breast Disease among First-Degree Relatives of Young Breast Cancer Patients

Similar documents
Risk Factors for Benign Breast Disease according to Histopathological Type: Comparisons with Risk Factors for Breast Cancer

Timing of Familial Breast Cancer in Sisters

Childhood Vaccination and Type 1 Diabetes

On the Clinical Importance of Benign Breast Disease: Causal Intermediary or Susceptibility Marker? Laura Reimers Iadeluca

ORIGINAL ARTICLE. Family History of Psychiatric Illness as a Risk Factor for Schizoaffective Disorder

The Relation of Surgery for Prostatic Hypertrophy to Carcinoma of the Prostate

Set-up of a population-based familial breast cancer registry in Geneva, Switzerland: validation of first results

Post-diagnosis NSAID use and risk of contralateral breast cancer

Susanne Oksbjerg Dalton, 1 Lene Mellemkjær, 1 Jørgen H. Olsen, 1 Preben B. Mortensen, 2 and Christoffer Johansen 1

Association of Clinical Benign Prostate Hyperplasia with Prostate Cancer Incidence and Mortality Revisited: A Nationwide Cohort Study of Men

Lower-Category Benign Breast Disease and the Risk of Invasive Breast Cancer

Incidence of Surgically Treated Benign Prostatic Hypertrophy and of Prostate Cancer among Blacks and Whites in a Prepaid Health Care Plan

Ann Rheum Dis 2017;76: doi: /annrheumdis Lin, Wan-Ting 2018/05/161

Cite this article as: BMJ, doi: /bmj (published 13 January 2005)

Appendix 4. Automation in cancer registration

The New England Journal of Medicine

Bleeding symptoms and subsequent risk of gynecological and other cancers

RESEARCH COMMUNICATION. Searching for Cancer Deaths in Australia: National Death Index vs. Cancer Registries

IJC International Journal of Cancer

Psychiatric Hospitalizations among Survivors of Cancer in Childhood or Adolescence

Survival of ovarian cancer patients in Denmark: Excess mortality risk analysis of five-year relative survival in the period

Prevalence of Hypospadias in Danish Boys: A Longitudinal Study,

So how much of breast and ovarian cancer is hereditary? A). 5 to 10 percent. B). 20 to 30 percent. C). 50 percent. Or D). 65 to 70 percent.

Extract from Cancer survival in Europe by country and age: results of EUROCARE-5 a population-based study

The Long-Term Risk of Epilepsy after Febrile Seizures in Susceptible Subgroups

Breast Cancer Risk and Progressive Histology in Serial Benign Biopsies

// Award Number: DAMD TITLE: Markers of Breast Cancer Risk in Women with Benign Breast Disease PRINCIPAL INVESTIGATOR:

A. Green, C. Sortsø, P.B. Jensen, M. Emneus

Fatal primary malignancy of brain. Glioblasatoma, histologically

1. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45

Utilization of BRCA Testing. Breast and Ovarian Cancer in Texas

The New England Journal of Medicine PROGNOSIS OF CANCERS ASSOCIATED WITH VENOUS THROMBOEMBOLISM. Study Design

Nipple Aspirate Fluid Cytology and the Gail Model for Breast Cancer Risk Assessment in a Screening Population

Examples of Nordic collaborations: benefits and challenges

Risk for anogenital cancer and other cancer among women hospitalized with gonorrhea

Atypical cancer pattern in patients with Parkinson s disease

Supplementary Appendix

Prophylactic Mastectomy

Cancer and pharmacoepidemiology in Finland. Information sources and research possibilities

Risk factors for breast cancer: relevance to screening

Birth Rate among Patients with Epilepsy: A Nationwide Population-based Cohort Study in Finland

Quantification of the effect of mammographic screening on fatal breast cancers: The Florence Programme

Growth Patterns and the Risk of Breast Cancer in Women

ORIGINAL ARTICLE. Psychiatric Disorders With Postpartum Onset. Possible Early Manifestations of Bipolar Affective Disorders

A follow-up study of breast and other cancers in families of an unselected series of breast cancer patients

Epidemiology of breast cancer in families in Iceland

S ocial status and health are strongly related and smoking

General practice. Abstract. Subjects and methods. Introduction. examining the effect of use of oral contraceptives on mortality in the long term.

Mammography and Other Screening Tests. for Breast Problems

Cite this article as: BMJ, doi: /bmj (published 22 June 2004)

breast cancer; relative risk; risk factor; standard deviation; strength of association

Cover Page. The handle holds various files of this Leiden University dissertation.

Report on Cancer Statistics in Alberta. Breast Cancer

Prophylactic Mastectomy

Chaim Sheba Medical Center Tel Hashomer Israel. Approved for public release; distribution unlimited

Diabetologia 9 Springer-Verlag 1983

FAMILIAL CARCINOID TUMORS AND SUBSEQUENT CANCERS: A NATION-WIDE EPIDEMIOLOGIC STUDY FROM SWEDEN

Breast cancer risk among women with psychiatric admission with affective or neurotic disorders: a nationwide cohort study in Denmark

Corporate Medical Policy Genetic Testing for Cutaneous Malignant Melanoma

Excess breast cancer risk and the role of parity, age at first childbirth and exposure to radiation in infancy

Oral contraceptives and breast disease

Linkage of Indiana State Cancer Registry and Indiana Network for Patient Care

Randomised study of screening for colorectal cancer with faecaloccult-blood

Childhood onset inflammatory bowel disease and risk of cancer: a Swedish nationwide cohort study

BARC/2013/E/019 BARC/2013/E/019. AUDIT OF MAMMOGRAPHY PERFORMED IN OUR HOSPITAL by Surita Kantharia Medical Division

The New England Journal of Medicine RADIAL SCARS IN BENIGN BREAST-BIOPSY SPECIMENS AND THE RISK OF BREAST CANCER

Risk of invasive cancer after colposcopy with and without biopsy

THE SAFETY OF THE MEASLES,

Risk Assessment, Genetics, and Prevention

Supplementary appendix: Oral polio vaccination and hospital admissions with non-polio infections in Denmark: Nationwide retrospective cohort study

ORIGINAL INVESTIGATION

Patient Education. Breast Cancer Prevention. Cancer Center

The Hot Topic for today is a biopsy from a 58-year-old woman who had worrisome mammographic calcifications on screening.

Supplementary Online Content

Benign breast disease (BBD) is a very common condition,

Dose-Related Differences in Effectiveness of Human Papillomavirus Vaccination Against Genital Warts: A Nationwide Study of Young Girls

THE AMERICAN ASSOCIATION OF PROLIFE OBSTETRICIANS AND GYNECOLOGISTS INDUCED ABORTION AND SUBSEQUENT BREAST CANCER RISK 2008

EFFECTS OF FAMILY HISTORY AND PLACE AND SEASON OF BIRTH ON THE RISK OF SCHIZOPHRENIA

Cytyc Corporation - Case Presentation Archive - March 2002

DRAFT. No. of cases/ deaths. categories. Number of X-ray exposures (for UK & Ireland only ever vs never)

12 CANCER Epidemiology Methodological considerations

Report on Cancer Statistics in Alberta. Kidney Cancer

Immunohistochemical studies (ER & Ki-67) in Proliferative breast lesions adjacent to malignancy

Ruolo della biopsia in colposcopia e rischio di carcinoma invasivo. Guglielmo Ronco AOU Città della salute e della scienza di Torino

Downloaded from:

Cancer survival and prevalence in Tasmania

The incidences of inflammatory bowel disease (IBD) 1 3

Prophylactic Mastectomy

Breast Evaluation & Management Guidelines

SIRI FORSMO,* BJARNE K JACOBSEN* AND HELGE STALSBERG t

Report on Cancer Statistics in Alberta. Melanoma of the Skin

Trial Designs. Professor Peter Cameron

Atypical proliferative lesions diagnosed on core biopsy - 6 year review

Factors Associated with Early Versus Late Development of Breast and Ovarian Cancer in BRCA1 and BRCA2 Positive Women

Original Policy Date

Spending estimates from Cancer Care Spending

Childhood Cancer Survivor Study Analysis Concept Proposal

Hormone therapy and ovarian borderline tumors: a national cohort study

RESEARCH. What is already known on this topic. What this study adds

Cancer in the Northern Territory :

Transcription:

American Journal of Epidemiology ª The Author 2008. Published by the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org. Vol. 168, No. 3 DOI: 10.1093/aje/kwn133 Advance Access publication June 4, 2008 Original Contribution Benign Breast Disease among First-Degree Relatives of Young Breast Cancer Patients Lisbeth Bertelsen 1, Lene Mellemkjær 1, Eva Balslev 2, and Jørgen H. Olsen 1 1 Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark. 2 Pathology Department, Herlev Hospital, Herlev, Denmark. Received for publication January 9, 2008; accepted for publication April 22, 2008. Benign breast disease is associated with increased risk of breast cancer. To further clarify whether there is a genetic link between benign and malignant breast lesions, the authors identified 14,648 first-degree female relatives of 8,807 patients in whom breast cancer was diagnosed at <50 years of age by using Danish nationwide cancer and population registers. Hospital register data were used to follow the relatives for occurrence of benign breast disease from 1977 to 2003 and to calculate rates of benign breast disease in the general population of Danish women for comparison. Risk for relatives was increased for benign breast diseases (observed/expected ratio ¼ 1.54, 95% confidence interval: 1.42, 1.66), particularly for relatives aged <40 years. Higher risks were observed after breast cancer had been diagnosed in the family; however, an increased risk for relatives aged <50 years (observed/ expected ratio ¼ 1.24, 95% confidence interval: 1.02, 1.51) was present before breast cancer was diagnosed in the family. Enhanced surveillance of close relatives of breast cancer patients seems to be an important factor to address when investigating the association between benign breast disease and familial breast cancer. A genetic link between benign breast disease and breast cancer was indicated by our data but needs to be confirmed in future studies. breast diseases; breast neoplasms; Denmark; family; linkage (genetics); registries; women Abbreviations: CI, confidence interval; ICD, International Classification of Diseases; O/E, observed/expected. The importance of heritability in the etiology of breast cancer is extensively documented (1, 2). Several studies (3 6), although not all (7, 8), have shown that a family history of breast cancer is also a risk factor for benign breast disease. Particularly strong associations have been reported for benign breast disease in young relatives (3, 5) and for atypical hyperplasia (3), indicating the existence of a genetic link between benign and malignant disease. The results of the studies published so far, however, may have been influenced by recall bias in the assessment of family history or by increased surveillance for breast diseases in families with known breast cancer cases, both potentially leading to false-positive associations. Here, we report the results of a large, population-based record-linkage study from Denmark on the occurrence of epithelial benign breast diseases in female relatives of women with early-onset breast cancer assessed from national population and cancer registers. The study was designed specifically to determine the rates of hospital contacts due to epithelial benign breast disease both before and after breast cancer was diagnosed in the family to address the issue of increased surveillance of families with known breast cancer cases. MATERIALS AND METHODS Index patients From the Danish population of women born in 1935 or later, we previously identified 2,857 women diagnosed with breast cancer at less than age 40 years during 1943 1990 (9). Correspondence to Lisbeth Bertelsen, Institute of Cancer Epidemiology, Danish Cancer Society, Strandboulevarden 49, DK-2100 Copenhagen, Denmark (e-mail: lisbethb@cancer.dk). 261

262 Bertelsen et al. TABLE 1. Data on index patients diagnosed with breast cancer at age <40 years during 1943 1999 and at age 40 49 years during 1991 1999, Denmark Age at breast cancer diagnosis (years) This material was updated by including 1,239 cases diagnosed during 1991 1999, for a total of 4,096 breast cancer cases diagnosed at less than age 40 years during 1943 1999 (table 1). In addition, we included 4,772 women diagnosed with breast cancer when they were 40 49 years of age during 1991 1999 (table 1). We restricted year of diagnosis for this age group because of constraints regarding the possibility of identifying relatives of older subjects in the Central Population Register (described below). Patients with breast cancer were identified from the files of the Danish Cancer Register on the basis of the International Classification of Diseases (ICD), Seventh Revision, code for breast cancer (ICD-7, code 170). For each patient, the register provided name, date of birth, and personal identification number. Completeness of registration of breast cancer in the Danish Cancer Register has been found to be 100 percent (10). Identification of female relatives Year of diagnosis of breast cancer <1991 1991 1999 The Central Population Register was established in Denmark on April 1, 1968, and includes all Danish inhabitants alive on this date or born thereafter who are assigned a unique personal identification number, which incorporates sex and date of birth and enables accurate linkage of information between registers. The Central Population Register maintains a cross-reference between parents and children for children born since the 1950s. The mothers of the 2,857 index patients younger than age 40 years diagnosed in 1943 1990 were identified by a computerized search of the Central Population Register using the personal identification number or, if this search was unsuccessful, by manual searches of relevant local parish and/or population registers. For nine women who died before 1968 and thus had no Central Population Register records, only manual searches were performed. The sisters of the patients were also located in the Central Population Register by use of the personal identification number of the mother or from local All No. % 10 14 1 0 1 0.0 15 19 2 0 2 0.0 20 24 40 10 50 0.6 25 29 268 93 361 4.1 30 34 807 344 1,151 13.0 35 39 1,739 792 2,531 28.5 All <40 2,857 1,239 4,096 46.2 40 44 1,728 1,728 19.5 45 49 3,044 3,044 34.3 All 40 49 4,772 4,772 53.8 All ages 2,857 6,011 8,868 100.0 population registers. Details of these procedures are given elsewhere (2). Family members of patients younger than age 40 years diagnosed in 1991 1999 were traced through the Central Population Register only. The mother was identified for 80 percent of the index patients in this group. For patients who were 40 49 years of age at diagnosis of breast cancer, family data were also available from only the Central Population Register. To avoid inclusion of too many patients without data on mother/sister in the Central Population Register, we restricted the years of breast cancer diagnoses to 1991 1999 for these patients. The search in the Central Population Register provided us with approximately 70 percent of the mothers of index patients born in the mid-1950s until 1959; for the subgroup of patients born before this period, a reference to their mother was provided for 10 percent. Daughters of all the breast cancer patients included were located through the Central Population Register by use of the personal identification numbers of the patients (except for the nine index patients who died before 1968, for whom searches for daughters were not performed). An overview of birth years and years of diagnosis of breast cancer in index patients is given in figure 1 (separately for those aged <40 years and those aged 40 years) as well as birth years for the relatives. Linkage of relatives to the files of the Central Population Register and the Danish mortality files provided the date of death or date of emigration, whichever was applicable. Probands and first-degree relatives To unambiguously define first-degree relatives of patients with early-onset breast cancer, we had to define the proband of the family. If the index patient was the only female member of the nuclear family who was affected by early-onset breast cancer, she became the proband. The search for family members revealed, however, that 49 pairs of the earlyonset breast cancer patients were sisters and 12 were mother-and-daughter pairs. In these 61 families, the woman whose breast cancer was diagnosed earliest was regarded as the proband. Thus, the 8,868 early-onset breast cancer patients were distributed in 8,807 different families. In these families, 15,311 female relatives (mothers, sisters, and daughters) were identified, of whom 14,648 (3,872 mothers, 3,043 sisters, and 7,733 daughters) were alive and free of breast cancer on January 1, 1977, when the Danish National Hospital Register was established. Table 2 gives selected information on the groups of female relatives. Follow-up for benign breast disease By use of the personal identification number, the relatives were linked to the files of the Danish National Hospital Register, which was instituted on January 1, 1977, and contains information on almost all hospitalizations for somatic diseases in Denmark (11). Since January 1, 1994, inpatient registration has been supplemented by information from outpatient visits. Each hospital visit initiates a record, which is flagged by the personal identification number and includes dates of admission and discharge, start and end dates

Familial Breast Cancer, Benign Breast Disease 263 FIGURE 1. Overview of how data on index patients and their first-degree female relatives and data from registries are distributed over calendar time, Denmark. of outpatient visits, one primary discharge diagnosis, and supplementary diagnoses. The diagnoses were coded according to a Danish version of the ICD, Eighth Revision (ICD-8) until the end of 1993 (12, 13) and according to the ICD, 10th Revision (14) thereafter. In the category of epithelial benign breast disease, we included benign breast tumor including fibroadenoma (ICD-8 code 217.1-9; ICD-10 code D24.9), fibroadenomatosis or other benign disorders of the breast (ICD-8 code 610.00; ICD-10 codes N60.2-3, N60.8-9), and benign breast cysts (ICD-8 codes 610.01, 610.08-09; ICD-10 codes N60.0-1, N60.4). From 1994 onward, we also included breast tumor, not otherwise specified (ICD-10 code N63.9). Follow-up of mothers, sisters, and daughters extended from January 1, 1977, or their 18th birthday, whichever occurred last, until the date of an epithelial benign breast disease or the censoring date defined as the date of breast cancer diagnosis, date of death, date of emigration, or the end of the study on December 31, 2003, whichever occurred first. If a woman had more than one diagnosis of benign breast disease, only the first diagnosis was counted. Both inpatient and outpatient diagnoses were included. Benign breast disease diagnosed less than 1 month before a diagnosis of breast cancer was disregarded in all analyses. The Danish Pathology Data Bank was used to validate the diagnoses of benign breast disease in the National Hospital Register. The Pathology Data Bank contains diagnoses coded according to a Danish modified version of the Systematized Nomenclature of Medicine (SNOMED) (15) since the early 1970s, with increasing coverage over time (16). An overview of the calendar years covered by the data from the various registers used (Central Population Register, Hospital Register, Pathology Data Bank) is shown in figure 1. Statistical analysis Occurrence of benign breast disease among the female relatives of women with early-onset breast cancer was compared with that for Danish women in general. Thus, for all women in Denmark who were free of breast cancer, we used information on inpatients and outpatients in the Danish National Hospital Register to calculate the rates for benign breast disease in 5-year age groups and calendar periods of

264 Bertelsen et al. TABLE 2. Numbers of first-degree female relatives of patients diagnosed with breast cancer at age <50 years, Denmark Relationship Numbers located Died/ emigrated Vital status and breast cancer status in 1977 Had breast cancer Were alive and breast cancer free Year of birth (range) Mothers 4,351 308 166 3,877* 1891 1954 Sisters 3,184 135 6 3,043 1914 1986 Daughters 7,776 43 0 7,733 1953 2003 All female relatives 15,311 486 172 14,648 1891 2003 * Five mothers, each the mother of two breast cancer patients (half-sisters), were counted only once. observation covering the study period 1977 2003. These age- and period-specific rates were applied to the appropriate person-years of observation to obtain the expected number of benign breast disease cases among the relatives. Ratios of observed to expected (O/E) cases of benign breast disease, and 95 percent confidence intervals, were computed on the assumption that the observed numbers followed a Poisson distribution. Risk analyses were stratified by type of familial relationship (mother, sister, or daughter), and outcomes were categorized according to age at diagnosis of benign breast disease (18 29, 30 39, 40 49, or 50 years). Risks of benign breast disease for relatives were also estimated separately for the periods preceding the date of diagnosis of early-onset breast cancer and for periods following that date. Finally, absolute measures were derived as the difference between the observed and expected rates (excess risk) of benign breast disease among relatives, and the associated attributable risk percentages were calculated as the excess risk divided by the observed rate. The latter gives an estimate of the percentage of cases of benign breast disease in relatives attributed to genetic factors shared by family members under the assumption that the association is causal. RESULTS For the 14,648 first-degree female relatives included in the study, 229,268 person-years of follow-up were accrued (median: 17 years; minimum: 8 days; maximum: 27 years). Overall, in the Hospital Register, we identified 634 female relatives with a diagnosis of benign breast disease during follow-up. Of these women, 45 percent (n ¼ 287) had an informative pathology record in the Pathology Data Bank within 2 months before or after the hospital diagnosis showing either no malignancy (n ¼ 65) or specific histologic information (n ¼ 222). Of the records that included histologic information, 91 percent (n ¼ 203) confirmed the diagnosis of a benign breast disease of epithelial origin. While the observed number of women with a hospital diagnosis of benign breast disease was 634, the expected number was 412.3, yielding a significantly increased O/E ratio of 1.54 (95 percent confidence interval (CI): 1.42, 1.66) and an excess risk of 9.7 cases of benign breast disease per 10,000 person-years at risk (table 3). The pattern of risk of benign breast disease by age of the relatives was quite similar for relatives of probands aged less than 40 years and relatives of probands aged 40 years or older at breast cancer diagnosis. The observed and expected rates of benign breast disease in relatives were clearly highest in the age range 30 49 years, while the relative risks of benign breast disease were highest in the age range 18 39 years. For the age group 40 years or older, the relative risks were only slightly increased. The relative risk was higher for the daughters (observed number ¼ 257; O/E ratio ¼ 1.87, 95 percent CI: 1.65, 2.11) than for the sisters (observed number ¼ 240; O/E ratio ¼ 1.48, 95 percent CI: 1.30, 1.68), with the lowest risk for the mothers (observed number ¼ 137; O/E ratio ¼ 1.21, 95 percent CI: 1.02, 1.43). However, stratification on age at diagnosis of benign breast disease in the relatives revealed that this ranking entirely reflected the age composition of the three groups of relatives (daughters: 99 percent of person-years at ages <40 years; sisters aged <40 years: observed number ¼ 116; O/E ratio ¼ 1.80, 95 percent CI: 1.49, 2.17; sisters aged 40 years: observed number ¼ 124; O/E ratio ¼ 1.27, 95 percent CI: 1.06, 1.33; mothers: 98 percent of person-years at ages 40 years). In a subanalysis, we estimated the relative risk of benign breast disease for female relatives before and after the date of diagnosis of the proband s breast cancer (table 3). A total of 80,141 person-years at risk among relatives were accumulated prior to the date of diagnosis of breast cancer in the proband, and 149,127 person-years were accumulated after that date. The risk of benign breast disease in relatives was significantly increased after the date of breast cancer diagnosis in the proband (O/E ratio ¼ 1.70, 95 percent CI: 1.55, 1.86) and borderline significantly increased before this date (O/E ratio ¼ 1.15, 95 percent CI: 0.97, 1.36). The excess risk of benign breast disease prior to the date of early-onset breast cancer in the family was 2.3 cases per 10,000 personyears, with an attributable risk percentage of 13. The O/E ratio before the date of the proband s breast cancer diagnosis was 1.24 (95 percent CI: 1.02, 1.51) among relatives aged 18 49 years. After the date of the proband s breast cancer diagnosis, the risk was twofold and was significantly elevated for relatives aged 18 39 years, whereas the risk was 1.3-fold and borderline significantly elevated for those in older age groups (table 3).

Familial Breast Cancer, Benign Breast Disease 265 TABLE 3. Denmark Risk of BBD* in first-degree relatives of breast cancer patients diagnosed at age <50 years, Relatives and age at risk of BBD (years) No. of personyears No. of BBD cases Rates per 10,000 person-years O/E* ratio 95% CI* Observed Expected Excess risky AR%*,z All female relatives 229,268 634 27.7 18.0 1.54 1.42, 1.66 9.7 35 Of probands aged <40 163,555 440 26.9 18.3 1.47 1.34, 1.62 8.6 32 years at breast cancer diagnosis Age at risk of BBD (years) 18 29 40,445 80 19.8 11.0 1.79 1.42, 2.23 8.8 44 30 39 28,360 139 49.0 26.2 1.87 1.57, 2.21 22.8 47 40 49 24,008 109 45.4 36.2 1.25 1.03, 1.51 9.2 20 50 70,743 112 15.8 13.1 1.21 0.99, 1.45 2.7 17 Of probands aged 40 years at breast cancer diagnosis 65,713 194 29.5 17.3 1.71 1.48, 1.96 12.2 41 Age at risk of BBD (years) 18 29 38,564 99 25.7 13.9 1.84 1.50, 2.24 11.7 46 30 39 9,899 60 60.6 29.8 2.04 1.55, 2.62 30.8 51 40 49 3,242 17 52.4 40.9 1.28 0.75, 2.06 11.6 22 50 14,010 18 12.8 12.2 1.05 0.62, 1.66 0.6 5 Person-years before breast 80,141 141 17.6 15.3 1.15 0.97, 1.36 2.3 13 cancer in proband Age at risk of BBD (years) 18 39 38,707 55 14.2 11.4 1.25 0.94, 1.63 2,8 20 40 49 10,556 47 44.5 36.5 1.22 0.90, 1.62 8.0 18 50 30,878 39 12.6 12.9 0.98 0.70, 1.34 0.3 2 Person-years after breast 149,127 493 33.1 19.4 1.70 1.55, 1.86 13.6 41 cancer in proband Age at risk of BBD (years) 18 39 78,559 323 41.1 20.1 2.04 1.83, 2.28 21.0 51 40 49 16,694 79 47.3 37.0 1.28 1.01, 1.60 10.4 22 50 53,875 91 16.9 13.0 1.30 1.04, 1.59 3.9 23 * BBD, benign breast disease; O/E, observed/expected; CI, confidence interval; AR%, attributable risk percentage. y Difference between observed and expected rate per 10,000 person-years. z Excess risk divided by the observed rate. DISCUSSION In this large, population-based follow-up study, we found that first-degree relatives of patients with early-onset breast cancer had significantly higher rates of hospital-based diagnoses of benign breast disease than women in the general population. The increase was clearest for daughters and sisters less than 40 years of age and after the date of diagnosis of breast cancer in the family. However, a significantly increased rate was also observed before the proband s diagnosis of breast cancer among relatives younger than age 50 years. Our overall findings of higher rates of benign breast diseases among women with a family history of breast cancer are in agreement with the results of a recent prospective cohort study of approximately 81,000 female nurses, which showed a significantly increased incidence of both self-reported physician diagnoses (rate ratio ¼ 1.38) and self-reported biopsy-confirmed diagnoses (rate ratio ¼ 1.67) of benign breast diseases among women reporting a family history of breast cancer at baseline compared with women who had reported no family history of breast cancer (3). Among women with proliferative disease, those with a family history were more likely than those with

266 Bertelsen et al. no family history to have atypical hyperplasia (3). Two casecontrol studies (4, 5) showed a positive association between a family history of breast cancer and the occurrence of benign breast disease, although, in one of the studies (5), the association was significant for premenopausal cases only. In two case-control studies (7, 8), the association was within the limits of chance; however, one of these studies included only breast cysts. A Japanese case-control study (6) reported that proliferative disease, but not nonproliferative disease, was associated with a positive family history of breast cancer in a mother or a sister. The results of the case-control studies were based on few cases, and the information on a family history of breast cancer was obtained by participant self-reports. The latter opens up the possibility of recall bias because the information was obtained from women after they had received a diagnosis of benign breast disease, except in the Japanese study (6). In the prospective study (3), the number of benign breast disease cases might have been falsely inflated because of increased surveillance of women who reported the occurrence of breast cancer in the family at baseline. More concern for and among young relatives in such families might also possibly explain why the association was strongest at young ages. In contrast to previous studies, we were able to estimate the risk of relatives receiving a hospital diagnosis of benign breast disease both before and after the breast cancer appeared in the family, thereby revealing any major effect of surveillance. Our results show a certain influence of enhanced surveillance because the excess was most pronounced after a family member received a diagnosis of breast cancer. However, among the youngest women, the incidence rate of benign breast disease was also significantly increased before the date of diagnosis, suggesting a genuine association between benign breast disease and a family history of breast cancer. If so, the aggregation of especially young benign breast disease cases in these families marked by early-onset breast cancer indicates a potential role of genetic factors. This prospect is supported by the results of methodical examinations of breasts removed prophylactically from carriers of mutations in the breast-cancerpredisposing genes, BRCA1 and BRCA2, which revealed high frequencies of both malignant and benign lesions (17). However, common risk factors for benign breast disease and breast cancer, including parity and age at birth of the first child (4, 6, 8, 18), may also contribute to familial aggregation. The strengths of our study include its size and the cohort design; the population-based approach, with unbiased identification of probands and female relatives from the combined use of national cancer and population registers; and hospital-based ascertainment of benign breast disease. In particular, we were able to estimate the rates of benign breast disease before the date of diagnosis of breast cancer in the family, approximately one third of the total number of person-years at risk occurring in the prediagnostic period. Although we restricted the years of breast cancer diagnoses to 1991 1999 for index patients diagnosed with breast cancer at ages 40 49 years, tracing of mothers and sisters for this group was incomplete. The main effect of this, however, should be reduction of sample size for relatives. It should not affect the validity of the findings because lack of the mother-daughter link in the Central Population Register is unlikely to be related to registration of benign breast disease among relatives in the Hospital Register. In relation to registration of diagnoses of benign breast disease in the Hospital Register, a higher degree of completeness was achieved when diagnoses made at outpatient visits were added to the register after 1994. Another limitation of our study is the use of diagnostic information on benign breast disease from a hospital register instead of pathology data. Validation was possible for only a subset of the hospital diagnoses, mainly because the Pathology Data Bank has not been complete over time. However, for diagnoses that could be validated by use of the Pathology Data Bank, the pathology record confirmed that more than 90 percent of the cases of benign breast disease were of epithelial origin. We found a 50 60 percent increase in the risk of firstdegree relatives of patients with early-onset breast cancer receiving a hospital diagnosis of benign breast disease. Our data suggest that increased surveillance of close relatives of breast cancer patients is likely to explain a substantial part of the increase, which emphasizes the need to control for surveillance in future studies. However, the finding of an elevated rate of benign breast disease at younger ages of the relatives prior to the date of breast cancer in the family indicates that genetic factors may possibly play a role in the increase in breast cancer risk for women with benign breast disease. ACKNOWLEDGMENTS This project was supported by the Danish Cancer Society. The authors thank Nick Martinussen and Andrea Bautz (from the Danish Cancer Society) for assistance with data management. Conflict of interest: none declared. REFERENCES 1. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 2001;358:1389 99. 2. Rawal R, Bertelsen L, Olsen JH. Cancer incidence in firstdegree relatives of a population-based set of cases of earlyonset breast cancer. Eur J Cancer 2000;42:3034 40. 3. Webb PM, Byrne C, Schnitt SJ, et al. Family history of breast cancer, age and benign breast disease. Int J Cancer 2002; 100:375 8. 4. Pastides H, Kelsey JL, Holford TR, et al. An epidemiologic study of fibrocystic breast disease with reference to ductal epithelial atypia. Am J Epidemiol 1985;121:440 7. 5. Berkowitz GS, Kelsey JL, LiVolsi VA, et al. Risk factors for fibrocystic breast disease and its histopathologic components. J Natl Cancer Inst 1985;75:43 50.

Familial Breast Cancer, Benign Breast Disease 267 6. Minami Y, Ohuchi N, Taeda Y, et al. Risk factors for benign breast disease according to histopathological type: comparisons with risk factors for breast cancer. Jpn J Cancer Res 1998;89:116 23. 7. Duffy SW, Roberts MM, Elton RA. Risk factors relevant to cystic breast disease: a case-control study. J Epidemiol Community Health 1983;37:271 3. 8. Nomura A, Comstock GW, Tonascia JA. Epidemiologic characteristics of benign breast disease. Am J Epidemiol 1977;105:505 12. 9. Olsen JH, Seersholm N, Boice JD Jr, et al. Cancer risk in close relatives of women with early-onset breast cancer a population-based incidence study. Br J Cancer 1999;79: 673 9. 10. Jensen AR, Overgaard J, Storm HH. Validity of breast cancer in the Danish Cancer Registry. A study based on clinical records from one county in Denmark. Eur J Cancer Prev 2002;11:359 64. 11. Andersen TF, Madsen M, Jorgensen J, et al. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999;46: 263 8. 12. Danish National Board of Health. Classification of diseases. 1st ed. Copenhagen, Denmark: Danish National Board of Health, 1976. 13. Danish National Board of Health. Classification of diseases. 2nd ed. Copenhagen, Denmark: Danish National Board of Health, 1986. 14. Danish National Board of Health. Classification of diseases. 10th rev. Copenhagen, Denmark: Danish National Board of Health, 1995. 15. Danish National Board of Health. Codebook for pathologicalanatomical examinations. SNOMED. 4th ed. Copenhagen, Denmark: Danish National Board of Health, 2002. 16. Vyberg M, Bjerregaard B, Bak M, et al. Pathology database. Danish Society of Pathologic Anatomy and Cytology. (In Danish). Ugeskr Læger 2005;167:1401. 17. Hoogerbrugge N, Bult P, de Widt-Levert LM, et al. High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer. J Clin Oncol 2003;21:41 5. 18. Goehring C, Morabia A. Epidemiology of benign breast disease, with special attention to histologic types. Epidemiol Rev 1997;19:310 27.